GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinphar Pharmaceutical Co Ltd (TPE:1734) » Definitions » Gross Profit

Sinphar Pharmaceutical Co (TPE:1734) Gross Profit : NT$1,237 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sinphar Pharmaceutical Co Gross Profit?

Sinphar Pharmaceutical Co's gross profit for the three months ended in Dec. 2024 was NT$348 Mil. Sinphar Pharmaceutical Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was NT$1,237 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Sinphar Pharmaceutical Co's gross profit for the three months ended in Dec. 2024 was NT$348 Mil. Sinphar Pharmaceutical Co's Revenue for the three months ended in Dec. 2024 was NT$854 Mil. Therefore, Sinphar Pharmaceutical Co's Gross Margin % for the quarter that ended in Dec. 2024 was 40.69%.

Sinphar Pharmaceutical Co had a gross margin of 40.69% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Sinphar Pharmaceutical Co was 39.29%. The lowest was 35.93%. And the median was 37.14%.


Sinphar Pharmaceutical Co Gross Profit Historical Data

The historical data trend for Sinphar Pharmaceutical Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinphar Pharmaceutical Co Gross Profit Chart

Sinphar Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 875.53 888.71 1,091.30 1,091.24 1,237.02

Sinphar Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 283.19 318.52 298.70 272.11 347.69

Competitive Comparison of Sinphar Pharmaceutical Co's Gross Profit

For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinphar Pharmaceutical Co's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Sinphar Pharmaceutical Co's Gross Profit falls into.


;
;

Sinphar Pharmaceutical Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Sinphar Pharmaceutical Co's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=3150.628 - 1913.612
=1,237

Sinphar Pharmaceutical Co's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=854.389 - 506.704
=348

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,237 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Sinphar Pharmaceutical Co's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=348 / 854.389
=40.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sinphar Pharmaceutical Co  (TPE:1734) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sinphar Pharmaceutical Co had a gross margin of 40.69% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Sinphar Pharmaceutical Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Sinphar Pharmaceutical Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinphar Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.84, Zhongshan Road, Dongshan Township, Zhongshan Village, Yilan, TWN, 269
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.

Sinphar Pharmaceutical Co Headlines

No Headlines